2024 - 2032 年局部药物 CDMO 市场机会、成长动力、产业趋势分析与预测

Topical Drugs CDMO Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032

出版日期: 2024年10月30日 | 出版商:

Global Market Insights Inc. | 英文 140 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2023 年，全球外用药物CDMO 市场达到437 亿美元，预计2024 年至2032 年复合年增长率为10.5%。输送系统为传统药物输送系统提供了更安全、更方便的替代品。随着患者和医疗保健提供者寻求能够以最小的全身影响进行有针对性的局部治疗的解决方案，包括乳膏、凝胶、软膏和透皮贴剂在内的局部製剂越来越受到关注。製药公司越来越多地将这些特殊药物的开发和製造外包给CDMO，后者提供必要的专业知识、先进的製造技术和监管合规性，使它们能够有效地满足外用药物生产不断变化的需求。市场按产品类型分为半固体、液体、透皮和固体製剂，其中半固体製剂处于领先地位，2023年将达到273亿美元。和凝胶，它们已成为治疗多种皮肤病的核心。

半固体製剂擅长将活性药物成分直接输送到受影响区域，使其在局部治疗中非常有效，同时减少全身吸收，在皮肤病学中尤其有价值。在治疗应用方面，外用药物CDMO市场分为皮肤科、疼痛管理、伤口护理和眼科等关键领域。由于皮肤病的流行和对有效治疗的需求，皮肤科是最大的细分市场，到 2023 年将占据 34.5% 的市场。痤疮、湿疹和牛皮癣等皮肤病影响着全世界数百万人，推动了对能够快速缓解症状的创新局部治疗的需求。

外用药物在皮肤科中特别受重视，因为它们能够将活性成分直接输送到受影响的区域，限制全身暴露并最大限度地减少副作用。美国外用药物 CDMO 市场预计将以 10.1% 的复合年增长率成长，到 2032 年将达到 350 亿美元，在这一全球扩张中发挥关键作用。该国受益于 CDMO 的强大存在，它们与製药公司密切合作，优化开发和製造流程，以加快新配方的上市时间。这些合作关係不仅简化了生产，还提高了产品品质和永续性，满足了对高效、环保的护肤解决方案日益增长的需求。

市场范围
开始年份	2023年
预测年份	2024-2032
起始值	437 亿美元
预测值	1059 亿美元
复合年增长率	10.5%

The Global Topical Drugs CDMO Market reached USD 43.7 billion in 2023 and is projected to grow at 10.5% CAGR from 2024 to 2032. This expansion is fueled by a rising demand for non-invasive drug delivery systems that offer safer and more convenient alternatives to traditional oral and injectable therapies. Topical formulations, including creams, gels, ointments, and transdermal patches, are gaining traction as patients and healthcare providers seek solutions that allow targeted, localized treatment with minimal systemic impact. Pharmaceutical companies are increasingly outsourcing the development and manufacturing of these specialized drugs to CDMOs, which provide essential expertise, advanced manufacturing technology, and regulatory compliance, allowing them to effectively meet the evolving demands of topical drug production. The market is segmented by product type into semi-solid, liquid, transdermal, and solid formulations, with semi-solid formulations leading the way, accounting for USD 27.3 billion in 2023. This segment includes various types of applications such as creams, ointments, and gels, which have become central to the treatment of numerous dermatological conditions.

Semi-solid formulations excel in delivering active pharmaceutical ingredients directly to affected areas, making them highly effective in localized treatments with reduced systemic absorption, especially valuable in dermatology. In terms of therapeutic applications, the topical drugs CDMO market is divided into key areas such as dermatology, pain management, wound care, and ophthalmology. Dermatology is the largest segment, holding 34.5% of the market share in 2023, driven by the prevalence of skin disorders and the need for effective treatments. Skin conditions, including acne, eczema, and psoriasis, impact millions worldwide, propelling the demand for innovative topical treatments that offer rapid relief.

Topical drugs are particularly valued in dermatology for their ability to deliver active ingredients directly to the affected areas, limiting systemic exposure and minimizing side effects. The U.S. topical drugs CDMO market, projected to grow at a 10.1% CAGR and reach USD 35 billion by 2032, plays a pivotal role in this global expansion. The country benefits from a strong presence of CDMOs collaborating closely with pharmaceutical companies, optimizing development and manufacturing processes to expedite time-to-market for new formulations. These partnerships not only streamline production but also enhance product quality and sustainability, aligning with the increasing demand for efficient and eco-friendly skincare solutions.

Market Scope
Start Year	2023
Forecast Year	2024-2032
Start Value	$43.7 Billion
Forecast Value	$105.9 Billion
CAGR	10.5%

Chapter 1 Methodology & Scope

1.1 Market scope & definition
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of skin disorder across the globe
  - 3.2.1.2 Growing adoption of outsourcing of manufacturing activities
  - 3.2.1.3 Growing aging population
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Challenges in quality control
  - 3.2.2.2 High capital investment
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Semi-solid formulations
- 5.2.1 Creams
- 5.2.2 Ointments
- 5.2.3 Gels
- 5.2.4 Other semi-solid formulations
5.3 Liquid formulations
5.4 Transdermal patches
5.5 Solid formulations

Chapter 6 Market Estimates and Forecast, By Therapeutic Area, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Dermatology
6.3 Pain management
6.4 Wound care
6.5 Ophthalmology
6.6 Other therapeutic areas

Chapter 7 Market Estimates and Forecast, By Service Type, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Contract manufacturing
7.3 Contract development

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Pharmaceutical companies
8.3 Biotechnology companies
8.4 Other end users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE